Suraksha Diagnostic Subscription Hits 0.06x on Day 2 as of 11:48 AM

Suraksha Diagnostic is one of the upcoming IPOs in India. The IPO opened for subscription on November 29, 2024, and closes on December 3, 2024. The allotment for the IPO is expected to be finalised on December 4, 2024. The shares are likely to be listed on Friday, December 6, 2024, on BSE and NSE.

Suraksha Diagnostic IPO is a book-built issue of ₹846.25 crore. The issue is entirely an offer for sale of 1.92 crore shares. The price band of the IPO is set at ₹420 to ₹441 per share. The minimum lot size for an application is 34 shares. Retail investors are required to invest a minimum amount of ₹14,994.

As of December 2, 2024, 9:26 AM, Suraksha Diagnostic GMP stands at ₹0.

Suraksha Diagnostic Subscription Status

• On Day 1, November 29, 2024, the IPO was subscribed 0.04 times. The retail category was subscribed 0.07x and the NII category was 0.02x.
• On Day 2, December 2, 2024, as of 11:48 AM, the IPO was subscribed 0.06 times. The retail category was subscribed 0.11x and the NII category was 0.04x.

About Suraksha Diagnostic Limited

Suraksha Diagnostic offers a wide range of pathology and radiology testing services, along with medical consultations, through its huge network. As of June 30, 2024, the network includes 8 satellite laboratories located within diagnostic centres, a flagship central reference laboratory, and 215 customer touchpoints. These touchpoints contain 49 diagnostic centres and 166 sample collection centres, mainly franchised, spread across Bihar, West Bengal, Assam, and Meghalaya.

In the three-month period ending June 30, 2024, the company conducted ~1.58 million tests, catering to around 0.28 million patients, with 95.34% of its operational revenue derived from Kolkata and the rest of West Bengal. For FY 2024, Suraksha Diagnostic performed ~5.98 million tests, serving 1.14 million patients, with 95.48% of its revenue also generated from its core market of Kolkata and West Bengal.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.